BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26515236)

  • 1. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma.
    Wei JH; Haddad A; Wu KJ; Zhao HW; Kapur P; Zhang ZL; Zhao LY; Chen ZH; Zhou YY; Zhou JC; Wang B; Yu YH; Cai MY; Xie D; Liao B; Li CX; Li PX; Wang ZR; Zhou FJ; Shi L; Liu QZ; Gao ZL; He DL; Chen W; Hsieh JT; Li QZ; Margulis V; Luo JH
    Nat Commun; 2015 Oct; 6():8699. PubMed ID: 26515236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
    Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
    BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
    Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
    Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma.
    Wang ZR; Wei JH; Zhou JC; Haddad A; Zhao LY; Kapur P; Wu KJ; Wang B; Yu YH; Liao B; He DL; Chen W; Margulis V; Hsieh JT; Luo JH
    Oncotarget; 2016 May; 7(21):31508-19. PubMed ID: 27129174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
    Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
    Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of amyloid A immunoexpression in the prognosis of renal cell carcinoma.
    Oz Atalay F; Aytac Vuruskan B; Vuruskan H
    APMIS; 2016 Apr; 124(4):257-62. PubMed ID: 26750935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.
    van Vlodrop IJ; Baldewijns MM; Smits KM; Schouten LJ; van Neste L; van Criekinge W; van Poppel H; Lerut E; Schuebel KE; Ahuja N; Herman JG; de Bruïne AP; van Engeland M
    Am J Pathol; 2010 Feb; 176(2):575-84. PubMed ID: 20042676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
    Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
    BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An effective seven-CpG-based signature to predict survival in renal clear cell carcinoma by integrating DNA methylation and gene expression.
    Xu L; He J; Cai Q; Li M; Pu X; Guo Y
    Life Sci; 2020 Feb; 243():117289. PubMed ID: 31926254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers.
    Joosten SC; Odeh SNO; Koch A; Buekers N; Aarts MJB; Baldewijns MMLL; Van Neste L; van Kuijk S; Schouten LJ; van den Brandt PA; Tjan-Heijnen VC; van Engeland M; Smits KM
    Clin Epigenetics; 2021 May; 13(1):103. PubMed ID: 33947447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Two-DNA Methylation Signature to Improve Prognosis Prediction of Clear Cell Renal Cell Carcinoma.
    Shi S; Ye S; Wu X; Xu M; Zhuo R; Liao Q; Xi Y
    Yonsei Med J; 2019 Nov; 60(11):1013-1020. PubMed ID: 31637882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of novel DNA methylation biomarkers for renal clear cell carcinoma.
    Kubiliūtė R; Žukauskaitė K; Žalimas A; Ulys A; Sabaliauskaitė R; Bakavičius A; Želvys A; Jankevičius F; Jarmalaitė S
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):361-375. PubMed ID: 34689221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Four-Gene Promoter Methylation Marker Panel Consisting of
    van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
    Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
    [No Abstract]   [Full Text] [Related]  

  • 16. Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma.
    Zheng J; Wang L; Peng Z; Yang Y; Feng D; He J
    EBioMedicine; 2017 Feb; 15():62-72. PubMed ID: 27993630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter DNA methylation analysis reveals a novel diagnostic CpG-based biomarker and RAB25 hypermethylation in clear cell renel cell carcinoma.
    Gu Y; Zou YM; Lei D; Huang Y; Li W; Mo Z; Hu Y
    Sci Rep; 2017 Oct; 7(1):14200. PubMed ID: 29079774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma.
    Haddad AQ; Luo JH; Krabbe LM; Darwish O; Gayed B; Youssef R; Kapur P; Rakheja D; Lotan Y; Sagalowsky A; Margulis V
    BJU Int; 2017 May; 119(5):741-747. PubMed ID: 28075543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Array‑based DNA methylation profiling.
    Kim YJ; Jang W; Piao XM; Yoon HY; Byun YJ; Kim JS; Kim SM; Lee SK; Seo SP; Kang HW; Kim WT; Yun SJ; Shon HS; Ryu KH; Kim SW; Ha YS; Yoon GS; Lee SC; Kwon TG; Kim WJ
    Oncol Rep; 2019 Jul; 42(1):453-460. PubMed ID: 31115548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases.
    Wuttig D; Zastrow S; Füssel S; Toma MI; Meinhardt M; Kalman K; Junker K; Sanjmyatav J; Boll K; Hackermüller J; Rolle A; Grimm MO; Wirth MP
    Int J Cancer; 2012 Sep; 131(5):E693-704. PubMed ID: 22213152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.